Scholar Rock (SRRK) Competitors

Genmab A/S (NASDAQ:GMAB) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.

Do insiders & institutionals have more ownership in GMAB or SRRK?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 19.2% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is GMAB or SRRK more profitable?

Genmab A/S has a net margin of 36.30% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 16.78% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Scholar Rock	N/A	-145.60%	-91.83%

Does the MarketBeat Community favor GMAB or SRRK?

Scholar Rock received 3 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 66.27% of users gave Scholar Rock an outperform vote while only 63.12% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 166 63.12%	Underperform Votes 97 36.88%
Scholar Rock	Outperform Votes 169 66.27%	Underperform Votes 86 33.73%

Which has more risk & volatility, GMAB or SRRK?

Genmab A/S has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Does the media refer more to GMAB or SRRK?

In the previous week, Genmab A/S had 1 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Genmab A/S and 9 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.02 beat Genmab A/S's score of 0.68 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings & valuation, GMAB or SRRK?

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$21.53B	0.60	$1.14B	$1.74	11.28
Scholar Rock	$33.19M	91.74	-$165.79M	-$2.45	-13.13

Do analysts rate GMAB or SRRK?

Genmab A/S presently has a consensus target price of $41.33, indicating a potential upside of 110.67%. Scholar Rock has a consensus target price of $40.86, indicating a potential upside of 27.04%. Given Genmab A/S's higher possible upside, equities analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.77
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Summary

Genmab A/S beats Scholar Rock on 11 of the 18 factors compared between the two stocks.